RxDoctor Payments Data

Robert Semlear, MD

Family Medicine · Ghent, NYNPI 1629163423

Payments from drug & device makers

$778in general payments, 2019–2025

Across 43 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$126
  • AstraZeneca$105
  • Pfizer$81
  • Novo Nordisk$81
  • Lilly USA, LLC$77
  • Amgen$59
  • plus $249 from 9 others

What the payments were for

  • Food & beverage$778100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$778 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$152
Medicare patients
21
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$86,394
TrulicityDulaglutide62$68,987
JardianceEmpagliflozin72$63,926
FarxigaDapagliflozin Propanediol56$41,467
OzempicSemaglutide18$27,361
XareltoRivaroxaban20$21,903
RybelsusSemaglutide22$20,508
MounjaroTirzepatide16$17,891
Breo ElliptaFluticasone/Vilanterol24$15,929
VascepaIcosapent Ethyl11$7,925
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$5,448
CreonLipase/Protease/Amylase11$5,024
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$4,467
Atorvastatin Calcium631$3,568
Insulin Lispro Kwikpen U-100Insulin Lispro11$3,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$77$86,87878 claims
PfizerEliquis$81$86,394105 claims
Boehringer IngelheimJardiance$57$63,92672 claims
Novo NordiskOzempic, Rybelsus$81$47,86940 claims
AstraZenecaFarxiga$105$41,46756 claims
GSKBreo Ellipta$29$15,92924 claims
AbbVieCreon, Synthroid$22$5,77032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Ghent

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →